SAGE Therapeutics (SAGE) Posts Q4 Loss of ~$1.57/Share

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of about ($1.57), $1.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• Activist Corvex seeks Whitbread board seat over strategy concerns